Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M508305200 on August 25, 2005

J. Biol. Chem., Vol. 280, Issue 45, 37995-38004, November 11, 2005
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
280/45/37995    most recent
M508305200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gallagher, M. J.
Right arrow Articles by Macdonald, R. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gallagher, M. J.
Right arrow Articles by Macdonald, R. L.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Endoplasmic Reticulum Retention and Associated Degradation of a GABAA Receptor Epilepsy Mutation That Inserts an Aspartate in the M3 Transmembrane Segment of the {alpha}1 Subunit*

Martin J. Gallagher{ddagger}1, Wangzhen Shen{ddagger}, Luyan Song{ddagger}, and Robert L. Macdonald{ddagger}§

From the Departments of {ddagger}Neurology, §Molecular Physiology and Biophysics, and Pharmacology, Vanderbilt University, Nashville, Tennessee 37232

Received for publication, July 28, 2005


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
A GABAA receptor {alpha}1 subunit epilepsy mutation ({alpha}1(A322D)) introduces a negatively charged aspartate residue into the hydrophobic M3 transmembrane domain of the {alpha}1 subunit. We reported previously that heterologous expression of {alpha}1(A322D){beta}2{gamma}2 receptors in mammalian cells resulted in reduced total and surface {alpha}1 subunit protein. Here we demonstrate the mechanism of this reduction. Total {alpha}1(A322D) subunit protein was reduced relative to wild type protein by a similar amount when expressed alone (86 ± 6%) or when coexpressed with {beta}2 and {gamma}2S subunits (78 ± 6%), indicating an expression reduction prior to subunit oligomerization. In {alpha}1{beta}2{gamma}2S receptors, endoglycosidase H deglycosylated only 26 ± 5% of {alpha}1 subunits, consistent with substantial protein maturation, but in {alpha}1(A322D){beta}2{gamma}2S receptors, endoglycosidase H deglycosylated 91 ± 4% of {alpha}1(A322D) subunits, consistent with failure of protein maturation. To determine the cellular localization of wild type and mutant subunits, the {alpha}1 subunit was tagged with yellow ({alpha}1-YFP) or cyan ({alpha}1-CFP) fluorescent protein. Confocal microscopic imaging demonstrated that 36 ± 4% of {alpha}1-YFP{beta}2{gamma}2 but only 5 ± 1% {alpha}1(A322D)-YFP{beta}2{gamma}2 colocalized with the plasma membrane, whereas the majority of the remaining receptors colocalized with the endoplasmic reticulum (55 ± 4% {alpha}1-YFP{beta}2{gamma}2S, 86 ± 3% {alpha}1(A322D)-YFP). Heterozygous expression of {alpha}1-CFP{beta}2{gamma}2S and {alpha}1(A322D)-YFP{beta}2{gamma}2S or {alpha}1-YFP{beta}2{gamma}2S and {alpha}1(A322D)-CFP{beta}2{gamma}2S receptors showed that membrane GABAA receptors contained primarily wild type {alpha}1 subunits. These data demonstrate that the A322D mutation reduces {alpha}1 subunit expression after translation, but before assembly, resulting in endoplasmic reticulum-associated degradation and membrane {alpha}1 subunits that are almost exclusively wild type subunits.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
GABAA2 receptors are pentameric ligand-gated chloride ion channels that are the major inhibitory neurotransmitter receptors in the mammalian central nervous system (1). The five subunits arise from seven subunit families that contain multiple subtypes and assemble in a limited number of subunit combinations, with the most prevalent consisting of two {alpha}1 subunits, two {beta}2 subunits, and one {gamma}2 subunit (2-5). Each subunit contains four hydrophobic segments (M1-M4) that are homologous to the four membrane spanning helices of the Torpedo marmorata nicotinic acetylcholine receptor (AChR) subunits whose three-dimensional structure has been determined to 4 Å (6).

A nonconserved missense mutation in the GABAA receptor {alpha}1 subunit gene (GABRA1, {alpha}1(A322D)) that codes for an aspartate in place of an alanine at position 7 of the M3 transmembrane segment is present in a form of autosomal dominant juvenile myoclonic epilepsy (7), an idiopathic generalized epilepsy syndrome that accounts for ~10% of all cases of epilepsy (8). When expressed in heterologous cells, this mutation affects both the function and expression of GABAA receptors. Expression of the {alpha}1(A322D) subunit with {beta}2 and {gamma}2 subunits ("homozygous expression") reduced peak currents by ~90%, substantially altered whole cell current kinetics, and reduced mean single channel open times (7, 9, 10). We recently reported that the {alpha}1(A322D) mutation reduced {alpha}1 subunit expression by 94%, and that it produced asymmetrical, subunit position-dependent reduction of heterozygous receptor currents and {alpha}1 subunit protein expression (10). Heterozygous receptors constructed from concatamers with the {alpha}1(A322D) subunit positioned between two {beta}2 subunits had 35% of peak current amplitudes and 70% of protein expression relative to wild type receptors, whereas heterozygous receptors with {alpha}1(A322D) positioned between {beta}2 and {gamma}2 subunits had 1% of peak current amplitude and 51% of protein expression of wild type receptors. To our knowledge, this is the first naturally occurring missense mutation that reduces expression of a ligand-gated ion channel subunit.

Because {alpha}1(A322D) substantially reduced the amount of {alpha}1 subunit, it is likely that it is this reduction in total {alpha}1 subunit expression, and not the alteration of GABAA receptor current kinetics, that is the predominant mechanism by which this mutation causes disinhibition and epilepsy. Here we determined the mechanism by which this single missense mutation reduced {alpha}1 subunit expression.


   MATERIALS AND METHODS
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Expression of recombinant GABAA Receptors—pcDNA3.1 plasmids containing cDNAs that encode human {alpha}1, {beta}2S, and {gamma}2S GABAA receptor subunits were a gift from Dr. Mathew Jones (University of Wisconsin, Madison, WI). {alpha}1-YFP and {alpha}-CFP cDNAs were constructed by first inserting HpaI and SacII restriction sites between the codons encoding amino acids four and five of the mature {alpha}1 subunit. DNA encoding the fluorescent protein (FP) from the corresponding {gamma}2S-FP subunit (11) was removed by HpaI and SacII digestion and then ligated into the {alpha}1 subunit-containing plasmid between the codons encoding amino acids four and five of the mature subunit. Cycle 3 GFP-tagged {alpha}1 subunit was constructed by performing a blunt ligation of the {alpha}1 subunit cDNA into cycle 3 GFP-containing pcDNA3.1 plasmid (Invitrogen). The {alpha}1(A322D) mutation was made using the QuikChange site-directed mutagenesis kit (Stratagene). All cDNA sequences were confirmed by DNA sequencing.

Human embryonic kidney cells (HEK293T) were a gift from P. Connely (COR Therapeutics, San Francisco, CA). Cells were grown at 37 °C in 5% CO2, 95% air using Dulbecco's modified Eagle's medium (Invitrogen) with 10% fetal bovine serum (Invitrogen) and 100 IU/ml streptomycin and penicillin (Invitrogen). Cells were transfected using the FuGENE 6 transfection reagent (Roche Diagnostics, 2.7 µl/µg of DNA). For the Western blot experiments, the cells were transfected in 6-cm dishes (Corning, Corning, NY) using 2:2:2 µg, {alpha}1:{beta}2S:{gamma}2S.

Transfections were similar for the electrophysiology experiments but also included 1 µg of pHOOK (Invitrogen), which was used for immunomagnetic separation (12). Twenty hours after transfection, cells were trypsinized, centrifuged (400 x g), and incubated with hapten-coated magnetic beads for 30 min at 37 °C. The cells that bound the magnetic beads were isolated via a magnetic stand and plated on 35-mm culture dishes.

For the confocal microscopy experiments, cells were transfected in 35-mm dishes using equal amounts (1 µg) of {alpha}1-FP, {beta}2S, and {gamma}2S subunit cDNAs. For the ER colocalization experiments, the cells were also transfected with 30 ng of a cyan fluorescent protein-tagged endoplasmic reticulum marker (CFP-ER, BD Biosciences).

Immunoblots—The Western blot protocol has been described (10). Transfected cells were lysed in modified radioimmunoassay solution (RIPA, 20 mM Tris, pH 7.4, 1% Triton X-100, 150 mM NaCl, 0.25% deoxycholate) that contained one pellet of Complete MiniTM protease inhibitor (Roche Diagnostics) per 10 ml. The lysates were centrifuged at 10,000 x g for 30 min. Lysates were fractionated by SDS-PAGE at the acrylamide concentrations given in the figure legends. After SDS-PAGE, the proteins were electrotransfered to polyvinylidene fluoride membranes (Millipore Inc.). All primary antibodies were monoclonal and were purchased from Chemicon Inc. (Temecula, CA). In experiments in which the cells were transfected with untagged {alpha}1 and {alpha}1(A322D) subunits, the membranes were first incubated with an antibody against the {alpha}1 subunit (5 µg/ml, clone BD24) in addition to an antibody against glyceraldehyde-3-phosphate dehydrogenase (GAPDH, 0.1 µg/ml, clone 6C5), which was used to control for the amount of protein loaded on the gel. For experiments in which the cells were transfected with FP-tagged {alpha}1 subunit, the membranes were incubated with a monoclonal antibody to green fluorescent protein (1:2500) as well as to an antibody to {beta}-actin (clone C4, 1 µg/ml). After incubation with the primary antibody, all immunoblots were incubated with a horseradish peroxidase-coupled goat anti-mouse secondary antibody (Jackson Immunoresearch Laboratories, 1:6000 dilution) and then visualized with a chemiluminescent detection system (Amersham Biosciences) using a digital imager (Alpha Innotech, San Leandro, CA). The integrated density volume (IDV, pixel intensity x mm2) of each band was calculated using the Alpha Innotech software. Background IDVs were obtained from regions adjacent to the bands of interest and subtracted from the total IDV. All protein bands were normalized to the loading control (GAPDH or actin).

Endoglycosidase Digestion—Protein lysates were prepared as described above and their protein concentrations were measured using the Micro BCA Protein AssayTM (Pierce). Endoglycosidase H (endo-H) and peptide N-glycosidase-F (PNGaseF) were obtained from Sigma. Endo-H and PNGaseF digestion of nicotinic AChR {delta}-subunit has been described (13). Both endoglycosidase digestions were performed for 3 h at 37 °C. Endo-H digestions were performed in 50 mM sodium citrate, pH 5.5, 1% Triton X-100, 0.1% SDS, 50 mM {beta}-mercaptoethanol with 0.2 units/ml endo-H. PNGaseF digestions were performed in 50 mM Tris-HCl, pH 7.4, 1% Triton X-100, 0.1% SDS, 50 mM {beta}-mercaptoethanol with 0.2 units/ml PNGaseF. The reactions were terminated by addition of Laemmli sample buffer, and the reaction products were detected by SDS-PAGE and Western blot as described above.

Confocal Microscopy and Image Analysis—Approximately 24 h before the confocal microscopy experiments, the transfected cells were plated in collagen-coated 35-mm glass-bottom dishes (MatTek, Ash-land, MA). The dishes were then coded, and thus the microscopy experiments were performed in a single-blinded fashion. Immediately before imaging, N-(3-triethylammoniumpropyl)-4-(6-(4-(diethylamino)phenyl)hexatrienyl)pyridinium dibromide (FM 4-64, 0.3 µg/ml, Invitrogen) was added to the culture media to stain the cells' plasma membranes without staining the ER (14). Cells were chosen at random and were imaged using a Zeiss 500 META confocal microscope with a x40, 1.3 numerical aperture Pan neofluoar objective. For all cells except those transfected with {alpha}1-CFP, the pinhole of all channels was adjusted so that the images were obtained as a single 2-µm slice through the middle of the cell. To collect more emitted light from the cells that were transfected with {alpha}1-CFP, the pinhole of all channels was adjusted so that the images were obtained as a single 3-µm slice through the middle of the cell. Excitation wavelengths were 455, 514, and 543 nm for CFP, YFP, and FM 4-64, respectively. For each excitation wavelength, the laser power was adjusted as necessary to utilize the full dynamic range of the detector for each respective fluorophore. CFP emission was detected with a 475-525-nm band pass filter, and FM 4-64 emission was detected using a 560-long pass filter. YFP emission was spectrally separated from CFP and FM 4-64 by reflecting the emitted light off a NFT545 dichroic mirror and then filtering it through a 530-600-band pass filter. The digital images were obtained with 2.8 times scanning zoom and 8 bit, 512 x 512 pixel resolution. All images presented in the figures are unprocessed.

The confocal image files were coded and processed in a single-blind fashion using the ImageJ software (National Institute of Health, Bethesda, MD). Background FP fluorescence for each image was obtained from cells that stained with FM 4-64 but did not express FP. Background CFP-ER fluorescence was defined as the CFP fluorescence in the nucleus. The background fluorescence was subtracted from the images at the 99th percentile. For cells cotransfected with CFP-ER, membrane YFP fluorescence was defined as the YFP outside the boundary of CFP-ER and FM 4-64 staining. For cells not cotransfected with CFP-ER, membrane FP fluorescence was defined as the FP outside the inner portion of FM 4-64 staining. ER YFP fluorescence was defined as intracellular YFP that colocalized with ER fluorescence. The integrated fluorescence from each subcellular region was calculated by summing all the background-subtracted fluorescence values from each pixel in that area.

Fluorescence Spectroscopy—Lysates of cells expressing {beta}2 and {gamma}2S subunits and wild type, heterozygous, or homozygous cycle 3 GPP-tagged {alpha}1 subunit ({alpha}1-GFP) were prepared as described above. Cycle 3 GFP was used to tag the {alpha}1 subunit for fluorescence spectroscopy rather than enhanced fluorescence proteins (CFP or YFP) because of its high fluorescence efficiency (15); it was not used for microscopy because its absorbance maximum is in the ultraviolet region of the spectrum. Ali-quots (200 µl) of the lysates were placed in microtiter plates, and the fluorescence was determined in a FlexstationTM fluorescence spectrometer (Molecular Devices, Sunnyvale, CA) with an excitation of 395 nm and emission of 507 nm. Background fluorescence was defined as the fluorescence from lysates from untransfected cells; the background was subtracted from the fluorescence of the experimental lysates.



View larger version (33K):
[in this window]
[in a new window]
  		FIGURE 1.
A and C, cells were transfected with equimolar ratios of {alpha}1, {beta}2, and {gamma}2S subunits; or B and D, {alpha}1 subunit and a 2-fold excess of empty pcDNA3.1 plasmid that was used to transfect equivalent masses of DNA. A and B, Western blots on 10% SDS-PAGE gels from whole cell lysates were probed with anti-{alpha}1 subunit antibody as well as an antibody against GAPDH, which was used to control for the amount of lysate protein loaded on the gel. C and D, the fraction of the {alpha}1 subunit band relative to the GAPDH band from each gel was quantified and averaged.

 
Electrophysiology—Electrophysiological recordings were performed 48 h after transfection. The intrapipette solution contained (in mM): 153 KCl, 1 MgCl2, 5 EGTA, 10 HEPES, and 2 MgATP (pH 7.3, osmolarity = 305-310 mOsm). The external recording solution consisted of (in mM): 142 NaCl, 8 KCl, 6 MgCl2, 1 CaCl2, 10 glucose, 10 HEPES (pH 7.4, osmolarity = 319-325 mOsm). Recording pipettes were pulled on a Sutter P-2000 micropipette electrode puller (Sutter Instrument Co., San Rafael, CA) from borosilicate capillary glass (Fisher). GABA was applied to the cells via gravity using a system consisting of pulled four-barrel square glass (200-300 µm) connected to a Perfusion Fast-Step (Warner Instrument Corp., Hamden, CT). The solution exchange time was determined by stepping a 10% dilute external solution across the open electrode tip to measure a liquid junction current; the 10-90% rise times for solution exchange were consistently ≤0.4 ms. GABAA receptor currents were recorded in voltage clamp mode with cells clamped at -50 mV using a lifted whole cell patch-clamp technique (16) using an Axon 200B amplifier (Molecular Devices). The signals were sampled at 10 kHz and written to a computer hard drive.

Homology Modeling and Secondary Structure Prediction—Multiple amino acid sequences were aligned using the ClustalW software (www.ebi.ac.uk/clustalw/). We identified amino acids of the M3 segments of the Torpedo marmorata AChR subunits that were homologous to the Ala-322 residue of the GABAA receptor {alpha}1 subunit in two steps. First, the following amino acid sequences were aligned in four groups: 1) Torpedo marmorata nAChR {alpha}, {beta}, {gamma}2, and {delta} subunits; 2) human GABAA receptor {alpha}1-6 subunits; 3) human GABAA receptor {beta}1-3 subunits; and 4) human {gamma}1-3 subunits. Next, the 16 sequences in these four groups were aligned together in conjunction with the human GABAA receptor {delta}-subunit, and the results of the 17-sequence alignment were visually compared with the small group analyses to make certain the sequences that were most similar with one another remained in alignment.

Identification and scoring of transmembrane helices were performed using the relevant ExPASY Proteomics tools (us.expasy.org/tools/) topology prediction algorithms (DAS, TopPred, TMPred, and TMHMM). The predictions were performed first on the native AChR sequences and then on the sequences in which the amino acid in the M3 domain homologous to the GABAA {alpha}1 subunit Ala-322 was changed to an aspartate. The scores from the topology prediction programs, which predicted a transmembrane helix for the 25-amino acid segments beginning at {alpha}Tyr-277, {beta}Tyr-283, {gamma}Tyr-291, and {delta}Tyr-286 (corresponding to the M3 transmembrane helices in the Torpedo marmorata electron diffraction data) for the sequences with or without the aspartate substitution, were compared.

Data Analysis—Values are reported as mean ± S.E. Statistical significance for the endoglycosidase, confocal, and fluorescence spectroscopy experiments were determined using the Student's unpaired t test and the significance of expression differences in the Western blot experiments and the effect of aspartate substitution on topology prediction scores were determined using the paired t test (GraphPad, San Diego, CA).


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
{alpha}1(A322D) Subunit Expression Was Reduced With or Without Coexpression with {beta}2 and {gamma}2S Subunits—GABAA receptor subunits oligomerize in the ER via distinct pathways (17) utilizing specific intersubunit contacts (18-23), and unassembled subunits are degraded (24). Because expression of {alpha}1(A322D){beta}2{gamma}2S receptors reduced currents and protein expression in a subunit position-dependent fashion (10), we hypothesized that {alpha}1(A322D) subunit mutation inhibited subunit oligomerization, thereby leading to mutant {alpha} subunit degradation. To test this hypothesis, we transfected cells with wild type {alpha}1 or heterozygous or homozygous {alpha}1(A322D) subunits and either wild type {beta}2 and {gamma}2S subunits ({alpha}1{beta}2{gamma}2S) or an equivalent amount of empty pcDNA3.1 plasmid ({alpha}1pcDNA) and performed Western blots on whole cell lysates (Fig. 1, A and B). The ratio of {alpha}1 subunit to GAPDH expression from whole cell lysates was determined by quantification of Western blots from whole cell lysates (Fig. 1, C and D). With transfection of both {alpha}1{beta}2{gamma}2S and {alpha}1pcDNA subunits, heterozygous {alpha}1 subunit expression was intermediate between those of wild type and the homozygous mutant {alpha}1 subunit expression (percentage of wild type expression of {alpha}1{beta}3{gamma}2S: n = 10, heterozygous 66 ± 6%, p = 0.045, homozygous 22 ± 6% p = 0.011; {alpha}1pcDNA n = 10: heterozygous 49 ± 6%, p = 0.005, homozygous 14 ± 6%, p = 0.003). There were no significant differences in the reduction of {alpha}1 subunit expression between cells transfected with {alpha}1{beta}2{gamma}2S subunits and those transfected with {alpha}1 subunits alone (heterozygous p = 0.061, homozygous p = 0.335). These results were unexpected because they indicated that that the {alpha}1(A322D) mutation reduced {alpha}1 subunit protein levels prior to receptor assembly.

{alpha}1(A322D) Was Endoglycosidase H Sensitive—A reduction in {alpha}1(A322D) subunit expression prior to receptor assembly could result from decreased efficiency of transcription or translation or from increased post-translational degradation of the mutant {alpha}1(A322D) subunit, known as ER-associated degradation (ERAD). If {alpha}1(A322D) subunit transcription or translation were reduced, the post-translational processing of residual {alpha}1(A322D) subunit would be similar to that of the wild type subunit. In contrast, accelerated ERAD would result in the residual {alpha}1(A322D) subunits having ER- but not Golgi-associated processing.

The {alpha}1 subunit has two sites of N-linked glycosylation that reside on its extracellular N terminus (17, 25). Membrane proteins are N-linked glycosylated with high mannose carbohydrates co-translationally within the ER, but upon trafficking to the trans-Golgi the high mannose carbohydrates are replaced with low mannose carbohydrates (26). Digestion with endo-H removes high mannose N-linked carbohydrates, whereas digestion with PNGaseF removes all carbohydrates. Therefore, endo-H sensitivity indicates a protein has not been trafficked at least as far as the trans-Golgi (27). To determine the glycosylation state of mutant {alpha}1(A322D) subunits, we digested cell lysates with endo-H or PNGaseF from cells transfected with wild type {alpha}1{beta}2{gamma}2S, heterozygous {alpha}1{alpha}1(A322D){beta}2{gamma}2S, and homozygous {alpha}1(A322D){beta}2{gamma}2S receptor subunits.



View larger version (47K):
[in this window]
[in a new window]
  		FIGURE 2.
A, lysates (2.5 mg/ml) from cells expressing wild type (WT), heterozygous (het), and homozygous (hom) receptors were left undigested (U) or digested with endo-H (H) or PNGaseF (F). Digestion products were fractionated via 12.5% SDS-PAGE and were loaded on the gel in the ratios 8:15:50, WT:heterozygous:homogenous, to balance the amount the {alpha}1 subunit protein. Western blots demonstrated that the {alpha}1 subunits from undigested lysates migrated at 50 kDa, and those digested with PNGaseF migrated at 46 kDa. Endo-H digestions of homogenous {alpha}1 subunit migrated in a single band at 46 kDa, but those of WT and heterozygous subunits migrated in two bands at 48.4 (endo-H resistant) and 46 kDa (endo-H sensitive). B, the fraction of endo-H-resistant {alpha}1 to total {alpha}1 subunit was plotted.

 



View larger version (12K):
[in this window]
[in a new window]
  		FIGURE 3.
Representative current traces obtained from wild type ({alpha}1-YFP{beta}2{gamma}2S) or homozygous ({alpha}1(A322D)-YFP{beta}2{gamma}2S, hom) after a 4-s step into 1 mM GABA. It should be noted that with transient transfections of GABAA receptors in HEK293T cells, there is a large variance in transfection efficiency and thus the peak currents depicted here do not reflect the mean peak currents of {alpha}1-YFP{beta}2{gamma}2S or {alpha}1(A322D)-YFP{beta}2{gamma}2S receptors.

 
Undigested cell lysates and those digested with endo-H or PNGaseF were analyzed by Western blot (Fig. 2, A and B). Because the wild type {alpha}1 subunit expresses more efficiently than heterozygous and homozygous {alpha}1 subunits, protein was loaded in the ratio WT:heterozygous: homozygous, 8:15:50 µg, to balance the amount of {alpha}1 subunit detected on the blot. Undigested wild type, heterozygous, and homozygous proteins ran at 50 kDa, and those digested with PNGaseF (removal of all N-linked carbohydrates) ran at 46 kDa, a reduction in molecular weight similar to PNGaseF digestion of Torpedo AChR {delta}-subunit (13) and tunicamycin inhibition of GABAA receptor 9E10-tagged {alpha}1 subunit glycosylation (17). With endo-H digestion, wild type and heterozygous receptors ran in two bands at 46 (endo-H sensitive) and 48.4 kDa (endo-H resistant), whereas endo-H digestion products of homozygous receptors ran in a single band at 46 kDa (Fig. 2, C and D). The 1.6-kDa shift in the endo-H-resistant band is similar to endo-H digestion of the AChR {delta}-subunit (13). Quantification of the 46- and 48.8-kDa digestion products demonstrated that 74 ± 5% of wild type (n = 6), 64 ± 4% of heterozygous (n = 6, p = 0.13), and 9 ± 4% (n = 6, p < 0.0001) of homozygous receptors were endo-H resistant. This shows that essentially all the homozygous {alpha}1(A322D) subunits retained ER processing and provides evidence that the defect in {alpha}1(A322D) subunit trafficking occurs after translation. Given the results of endo-H digestion of wild type and homozygous {alpha}1 subunits, with independent processing of these subunits, 42, not 64%, of heterozygous {alpha}1 subunit should have been endo-H sensitive. This suggests that other processes (such as protein degradation) may alter the relative ratios of wild type {alpha}1 and {alpha}1(A322D) subunits. Another alternative is that this assay lacks the resolution and statistical power to detect a difference in the extent of glycosylation between wild type and heterozygous receptors.

{alpha}1-YFP{beta}2{gamma}2S and{alpha}1(A322D)-YFP{beta}2{gamma}2S Receptors Were Functional—To further characterize the subcellular localization of wild type and mutant {alpha}1 subunits, we constructed YFP-tagged wild type ({alpha}1-YFP) and mutant ({alpha}1(A322D)-YFP) subunits. Electrophysiological analysis of N-terminal fluorescent-tagged {gamma}2-subunit-containing GABAA receptors has been performed in fibroblasts (11, 28), and electrophysiological analysis of GABAA receptors containing {alpha}1 subunits tagged with GFP at the C terminus has been done in oocytes (29). We evaluated GABA-evoked currents in cells transfected with GABAA receptors containing wild type or mutant {alpha}1 subunits tagged with YFP at the N terminus. Currents were evoked from both wild type {alpha}1-YFP{beta}2{gamma}2S (n=7) and homozygous {alpha}1(A322D)-YFP{beta}2{gamma}2S (n = 5) receptor suponapplication of 1 mM GABA (Fig. 3). Wild type {alpha}1-YFP{beta}2{gamma}2S receptors, but not the homozygous {alpha}1(A322D)-YFP{beta}2{gamma}2S receptors, had fast phases of GABA-evoked desensitization, and thus the current kinetics were similar to those of the respective non-FP-tagged receptors (9, 10). Thus, adding a fluorescent protein at the N terminus of the GABAA receptor {alpha}1 subunit did not substantially change the properties of wild type or {alpha}1(A322D) mutant {alpha}1 subunit currents evoked by 1 mM GABA.

{alpha}1-YFP and {alpha}1(A322D)-YFP Subunit-containing Receptors Had Similar Relative Expression Levels, but Different Processing Than Non-{alpha}1-YFP-tagged Receptors—To determine whether {alpha}1(A322D) altered expression of {alpha}1-FP subunits, we performed fluorescence spectroscopy on whole cell lysates from cells transfected with {beta}2 and {gamma}2S subunits and wild type, heterozygous, and cycle 3 GFP-tagged-{alpha}1 subunits. Measuring the fluorescence intensity of a whole cell lysate rather than from individual cells during microscopy gives the mean fluorescence of the sample and avoids cell-to-cell variability that would be obtained during microscopy. Wild type {alpha}1-GFP{beta}2{gamma}2S receptor fluorescence (18,093 ± 1096, arbitrary fluorescence units, AFU) was greater than heterozygous {alpha}1-GFP{alpha}1(A322D)-GFP{beta}2{gamma}2S receptor fluorescence (10,870 ± 626 AFU), and heterozygous {alpha}1-GFP{alpha}1(A322D)-GFP{beta}2{gamma}2S receptor fluorescence was greater than homozygous {alpha}1(A322D)-GFP{beta}2{gamma}2 receptor fluorescence (3,922 ± 1100 AFU, n = 4, p < 0.001, Fig. 4A). Thus, A322D reduced {alpha}1-GFP fluorescence to a similar extent as it reduced protein expression of non-FP-tagged {alpha}1 subunit (Fig. 1).

As a second method to determine the effect of {alpha}1(A322D) on the expression of the {alpha}1-YFP subunit, we performed Western blots using an anti-GFP antibody on whole cell lysates from cells transfected with wild type, heterozygous, and homozygous {alpha}1-YFP subunits with cotransfection of {beta}2 and {gamma}2S subunits or an equivalent amount of empty pcDNA3.1 plasmid (Fig. 4B). For both wild type and heterozygous {alpha}1{beta}2{gamma}2S receptors as well as {alpha}1-YFP subunits transfected alone, there were two specific immunoreactive bands at 64 and 72 kDa (n = 6). For homozygous {alpha}1(A322D)-YFP{beta}2{gamma}2S receptors, there was only one specific immunoreactive band at 64 kDa.



View larger version (36K):
[in this window]
[in a new window]
  		FIGURE 4.
A, fluorescence spectroscopy of whole cell lysates of cycle 3 GFP-tagged {alpha}1-GFP{beta}2{gamma}2S receptors demonstrated differences in mean GFP fluorescence among wild type (18,093 ± 1,096 AFU), heterozygous (10,870 ± 626), and homozygous (3,922 ± 1,100, n = 4, p < 0. 001) receptors. B, cells were transfected with wild type ({alpha}1-YFP), heterozygous (het, {alpha}1-YFP{alpha}1(A322D)-YFP), or homozygous (hom, {alpha}1(A322D)-YFP) {alpha}1-YFP subunits and either {beta}2 and {gamma}2S subunits or an equivalent mass of empty pcDNA3.1 plasmid. Lysates from cells that were untransfected (ut) were loaded to define nonspecific immunoreactivity. For both the cells that co-expressed {beta}2 and {gamma}2S subunits as well as those that expressed only {alpha}1-YFP/pcDNA3.1, wild type and heterozygous subunits ran in two immunospecific bands at 72 and 64 kDa. Homozygous {alpha}1(A322D)-YFP subunit ran as a single immunospecific band at 64 kDa. C, the total immunoreactive protein from the Western blots from {alpha}1-YFP{beta}2{gamma}2S; and D, {alpha}1-YFP alone transfections were quantified and presented both as a fraction of total wild type YFP-{alpha} subunit. E and F, the fraction of the 64- and 72-kDa bands from {alpha}1-YFP{beta}2{gamma}2S receptors and {alpha}1-YFP subunits are presented as the fraction of the total wild type band.

 
The bands were quantified, and for each lane, the IDVs were divided by the IDV of actin, which served as a control for the amount of protein loaded in each lane of the gel (Fig. 4, C-E). For {alpha}-YFP{beta}2{gamma}2S receptors, the total IDV:actin ratio of the two immunoreactive bands for the wild type receptors (normalized to 100%) was greater than those of heterozygous and homozygous receptors (heterozygous 57 ± 6%, p = 0.038, homozygous 46 ± 4%, p = 0.037) (Fig. 4C). A similar trend was observed for cells transfected with the {alpha}1-YFP subunit alone (heterozygous 92 ± 12%, p = 0.377, homozygous 56 ± 5.8%, p = 0.030) (Fig. 4D), although the difference between wild type and heterozygous was not statistically significant. Thus, for cells transfected with {alpha}1-YFP subunit alone or cotransfected with {alpha}1-YFP{beta}2{gamma}2S subunits, wild type {alpha}1-YFP subunit expression was greater than heterozygous {alpha}1-YFP{alpha}1(A322D)-YFP subunit expression, and heterozygous {alpha}1-YFP{alpha}1(A322D)-YFP subunit expression was greater than homozygous {alpha}1(A322D)-YFP subunit expression. These results were in agreement with those obtained with non-YFP-tagged receptors (Fig. 1). However, for both cells transfected with {alpha}1-YFP{beta}2{gamma}2S subunits as well as those transfected with {alpha}1-YFP subunit alone, the fraction of homozygous {alpha}1(A322D)-YFP subunit to wild type {alpha}1-YFP subunit was greater than that for the non-YFP-tagged receptors.

The amounts of expression of the 72- and 64-kDa bands were quantified individually (Fig. 4, E and F). Because distinct 72-kDa bands could not be visually identified for homozygous receptors, we quantified the IDV from the region of the homozygous lanes that corresponded to the 72-kDa bands from the wild type lanes. The 64-kDa band from wild type {alpha}1-YFP{beta}2{gamma}2S receptors was smaller (38 ± 3.0% of wild type total) than the 72-kDa band (62 ± 3.0% of wild type total), but for the heterozygous {alpha}1-YFP{alpha}1(A322D)-YFP{beta}2{gamma}2S and homozygous {alpha}1(A322D)-YFP{beta}2{gamma}2S receptors, the 64-kDa bands (heterozygous 32 ± 3.3%; homozygous 37 ± 4.6% wild type total) were larger than the 72-kDa bands (heterozygous 25 + 3.4% p = 0.009; homozygous 8.7 ± 1.8%, p = 0.015 wild type total) (Fig. 4E). For the cells in which the {alpha}1-YFP subunit was transfected alone, expression of the wild type 64-kDa band (48 ± 3.2% total wild type) was smaller than the 72-kDa band (52 ± 3.2% wild type), but expression of the heterozygous and homozygous 64-kDa band (heterozygous 55 ± 7.7%, homozygous 40 ± 4.6% total wild type) was larger than the 72-kDa band (heterozygous 38 ± 5.5%, p = 0.026; homozygous 16 ± 2.7%, p = 0.011) (Fig. 4F).

The difference in both the total {alpha}1-YFP subunit expression as well as the ratios of the 64- to 72-kDa bands among the different transfection states could be attributed exclusively to differences in the expression of the 72-kDa band. The 72-kDa band in heterozygous {alpha}1-YFP{alpha}1(A322D){beta}2{gamma}2S receptors was 40 ± 4% (p < 0.001) of the wild type 72-kDa band, whereas the 72-kDa band from homozygous {alpha}1(A322D)-YFP was 15 ± 3% (p < 0.001) of the wild type 72-kDa band. For cells transfected with {alpha}1-YFP subunit alone, the heterozygous {alpha}1-YFP{alpha}1(A322D) subunit 72-kDab and was 63 ± 13% (p=0.045) of the wild type 72-kDa band, and the homozygous {alpha}1(A322D)-YFP subunit kDa band was 26 ± 5.8% (p < 0.0001) of the wild type 72-kDa band. In contrast, there were no significant differences among the wild type, heterozygous, and homozygous 64-kDa bands from either {alpha}1{beta}3{gamma}2S receptors (heterozygous = 79 ± 11%, p = 0.770; homozygous 86 ± 8%, p = 0.888) or from {alpha}1-YFP subunit expressed alone (heterozygous 108 ± 22%, p = 0.414; homozygous 83 ± 9.6%, p = 0.214).



View larger version (27K):
[in this window]
[in a new window]
  		FIGURE 5.
The 64-kDa band in {alpha}1-YFP-containing receptors is the deglycosylated form of the 72-kDa band. Cells were transfected with wild type ({alpha}1-YFP{beta}2{gamma}2S) or heterozygous (het, {alpha}1-YFP/{alpha}1(A322D)-YFP{beta}2{gamma}2S) {alpha}1-YFP and either {beta}2 and {gamma}2S subunits or an equivalent mass of pcDNA3.1 plasmid. The lysates were either left undigested (U) or digested with endo-H (H) or PNGaseF (F) and analyzed by 10% SDS-PAGE Western blots and probed with a monoclonal antibody targeted against GFP as well as an antibody against actin that controlled for the amount of loaded lysate. For the cells transfected with {beta}2 and {gamma}2S subunits, PNGase F, but not endo-H digestion shifted all the 72-kDa band to 64 kDa. For the cells transfected with {alpha}1-YFP subunits without {beta}2 or {gamma}2S subunits, both endo-H and PNGaseF shifted the migration of the bands from 72 to 64 kDa (n = 3). Undigested wild type and heterozygous but not homozygous receptors migrated in two bands at 64 and 72 kDa; all YFP-GABAA receptor digested with PNGaseF migrated at 64 kDa. PNGaseF digestion of homozygous {alpha}1(A322D)-YFP{beta}2{gamma}2S receptors did not alter the migration of the 64-kDa specific immunoreactive band (not shown).

 
These data demonstrate that similar to the non-YFP-tagged {alpha}1 subunits, the {alpha}1(A322D) mutation reduced expression of {alpha}1-FP subunits. It had been reported recently that Western blots of whole cell lysates from cells expressing GABAA receptors containing {alpha}1(A322D)-GFP subunits demonstrated the presence of the {alpha}1(A322D)-GFP subunit. From this, it was concluded that {alpha}1(A322D) does not preclude {alpha}1 subunit expression (30). Here we also show that {alpha}1(A322D)-YFP is expressed. However, our quantification of the Western blots demonstrated that its expression was reduced, a result confirmed by measurement of {alpha}1(A322D)-GFP fluorescence.

The addition of YFP to the N terminus of the {alpha}1 subunit did change some aspects of its processing. First, {alpha}1(A322D)-YFP expression relative to wild type expression (46 ± 4%) was greater than that of the non-FP-tagged receptors (22 ± 6%, Fig. 1). Second, on Western blot, {alpha}1-YFP ran as bands of two different molecular weights. One possibility is that the presence of the large YFP epitope tag on the N terminus interfered with N-glycosylation of the subunit.

{alpha}1-YFP, but Not {alpha}1(A322D)-YFP, Is N-Glycosylated—In contrast to the non-YFP-tagged {alpha}1 subunits that migrated in one band (Fig. 1), the wild type and heterozygous {alpha}1-YFP subunits migrated in two bands when expressed alone or with {beta}2 and {gamma}2S subunits. To determine whether the two {alpha}1-YFP subunit bands represented differentially glycosylated forms of {alpha}1-YFP subunit, we digested wild type {alpha}1-YFP{beta}2{gamma}2S receptors and {alpha}1-YFP subunits with endo-H and PNGaseF (Fig. 5). For both {alpha}1-YFP{beta}2{gamma}2S receptors (n = 11) and the {alpha}1-YFP subunit alone (n = 5), PNGaseF digestion resulted in a single specific immunoreactive band (anti-GFP antibody) that ran at 64 kDa. This demonstrated that the 72-kDa band was a glycosylated form of the 64-kDa band. PNGaseF digestion (not shown) of heterozygous {alpha}1-YFP{alpha}1(A322D){beta}2{gamma}2S receptors (n = 8) and {alpha}1-YFP{alpha}1(A322D) subunits (n = 3) also resulted in a single specific immunoreactive band at 64 kDa. PNGaseF digestion of homozygous {alpha}1(A322D)-YFP{beta}2{gamma}2S receptors (n = 7) did not shift the {alpha}1-YFP subunit apparent molecular weight (not shown).

Endo-H digestion products of wild type {alpha}1-YFP{beta}2{gamma}2S receptors (n = 4) ran as two bands with apparent molecular masses of 72 and 64 kDa, thus demonstrating that these receptors contained low mannose glycosylation and were thus processed in the trans-Golgi. In contrast, endo-H digestion of cell lysates transfected with {alpha}1-YFP subunits alone (n = 4) ran as a single band at 64 kDa, indicating maturation arrest in the ER.

Interestingly, although non-YFP-tagged {alpha}1 and {alpha}1(A322D) subunits had substantially different fractions of endo-H-sensitive N-linked glycosylation, each was 100% glycosylated (Fig. 2). In contrast, only 85% of wild type {alpha}1-YFP and 15% of {alpha}1(A322D)-YFP subunits were glycosylated. This highlights the fact that even though fluorescently tagged {alpha}1 subunits form GABAA receptors with similar functional properties as native receptors (Fig. 3), and that the A322D mutation causes qualitatively similar reductions in {alpha}1-YFP subunits as with non-fluorescently tagged {alpha}1 subunits (Fig. 4), there do exist some differences in post-translational glycosylation

Assembled, but Not Unassembled, {alpha}1-YFP Subunits Localized to the Membrane—It has been shown that 9E10-tagged {alpha}1 subunit homomers do not traffic to the plasma membrane, but, instead, are sequestered in the ER (17) and degraded (24). Likewise, {alpha}1 subunit homomers tagged with GFP at the C terminus remain in the ER of oocytes (29). We tested the ability of {alpha}1-YFP subunits to traffic to cell membranes with and without coexpression of {beta}2 and {gamma}2S subunits. Cells were transfected with CFP-ER, YFP-{alpha}1 subunit, and either {beta}2 and {gamma}2S subunits or an equivalent amount of pcDNA3.1. The cells were imaged by confocal microscopy (Fig. 6A). Although the ER extends to the plasma membrane in these cells, dual labeling of the ER and membrane compartments allowed reliable separation of the ER component from the membrane component. Thus, the fraction of {alpha}-YFP subunit colocalized to the membrane and ER could be quantified (Fig. 6B). For receptors transfected with {alpha}1-YFP subunit and empty pcDNA3.1, 80 ± 3% of the {alpha}1-YFP subunit colocalized to the ER and 6.5 ± 0.8% colocalized to the membrane (n = 11). In contrast, for receptors transfected with {alpha}1-YFP, {beta}2, and {gamma}2S subunits, 55 ± 4% of the {alpha}1-YFP subunit colocalized in the ER (p < 0.001) and 36 ± 4% colocalized with the plasma membrane (p < 0.001, n = 13). Thus, assembled, but not unassembled, {alpha}1-YFP subunits were localized to the membrane.

The {alpha}1(A322D)-YFP Subunit Localizes to the ER—To determine the subcellular localization of {alpha}1(A322D)-YFP subunits, we transfected cells with CFP-ER and either wild type {alpha}1-YFP{beta}2{gamma}2S, heterozygous {alpha}1-YFP{alpha}1(A322D)-YFP{beta}2{gamma}2S, or homozygous {alpha}1(A322D)-YFP{beta}2{gamma}2S receptors. Visual analysis of confocal images of these cells demonstrated that the majority of the {alpha}1-YFP subunit for wild type, heterozygous, and homozygous receptors colocalized with the ER (Fig. 7A). Only wild type and heterozygous cells had identifiable {alpha}-YFP subunit colocalized with the membrane. There were no distinct intracellular inclusions of {alpha}-YFP subunits for any of the transfection states.

Quantification of the YFP distribution (Fig. 7B) demonstrated that the fraction of total {alpha}1-YFP subunit colocalized with the membrane was 36 ± 4% for wild type (n = 13), 20 ± 3% for heterozygous (n = 12, p = 0.003), and 4.8 ± 0.6% for homozygous (n = 10, p = 0.003) receptors. In contrast, the percentage of YFP fluorescence colocalized with the ER was least for wild type (55 ± 4%), intermediate for heterozygous (70 ± 3%, n = 12, p = 0.008), and most for homozygous (86 ± 2%, n = 10, p = 0.001) receptors. There were no differences in the percentage of {alpha}1-YFP subunit that was intracellular, but outside the ER (p > 0.70).



View larger version (33K):
[in this window]
[in a new window]
  		FIGURE 6.
A, cells were transfected with {alpha}1-YFP and either {beta}2 and {gamma}2S subunits or an equivalent mass of pcDNA3.1. Confocal microscopy demonstrated that for both transfections, {alpha}-YFP (R, green) receptors co-localized with the CFP-ER (ER, blue). However, only the receptors co-transfected with {beta}2 and {gamma}2S subunits localized to the plasma membrane (M, red). Colocalization (Co) of {alpha}1-YFP and CFP-ER is cyan and colocalization of {alpha}-YFP and the membrane marker is yellow. B, the fraction of total {alpha}1-YFP/{beta}2/{gamma}2 and {alpha}1-YFP/pcDNA that colocalized to the membrane or ER is graphed.

 



View larger version (49K):
[in this window]
[in a new window]
  		FIGURE 7.
A, cells were transfected with wild type ({alpha}1-YFP{beta}2{gamma}2S), heterozygous (het, {alpha}1-YFP{alpha}1(A322D)-YFP{beta}2{gamma}2S), homozygous (hom, {alpha}1(A322D)-YFP{beta}2{gamma}2S) receptors (R, green) as well as CFP-ER (ER, blue) and labeled with FM 4-64 (M, red). The majority of wild type, heterozygous, and homozygous {alpha}1-YFP subunit colocalized (Co) with the ER (cyan). Only wild type and heterozygous {alpha}1-YFP subunit colocalized with the plasma membrane FM 4-64 marker (yellow). B, the fraction of total wild type, heterozygous, and homozygous {alpha}1-YFP that colocalized to the membrane or ER is graphed.

 
Membrane {alpha}1-YFP Subunits with Heterozygous Expression Are Derived from Wild Type {alpha}1-YFP, but Not Mutant {alpha}1(A322D)-YFP, Subunits—Individuals with autosomal dominant juvenile myoclonic epilepsy are heterozygous for the {alpha}1(A322D) mutation (7), and thus it was of interest to determine the relative amounts of wild type {alpha}1 and mutant {alpha}1(A322D) subunit that were trafficked to the plasma membrane with heterozygous expression. We constructed CFP-tagged wild type ({alpha}1-CFP) and mutant ({alpha}1(A322D)-CFP) subunits. Cells that were heterozygous for the {alpha}1(A322D) subunit mutation were formed by cotransfecting either wild type {alpha}1-YFP and mutant {alpha}1(A322D)-CFP subunits or wild type {alpha}1-CFP and mutant {alpha}1(A322D)-YFP subunits. Visual analysis of confocal microscopic images demonstrated that with both {alpha}1-YFP{alpha}1(A322D)-CFP{beta}2{gamma}2S and the {alpha}1-CFP{alpha}1(A322D)-YFP{beta}2{gamma}2S transfections, the only apparent cell surface fluorescence originated from the wild type {alpha}1-FP subunit protein (Fig. 8A).



View larger version (33K):
[in this window]
[in a new window]
  		FIGURE 8.
A, cells were transfected with either {alpha}1-YFP{alpha}1(A322D)-CFP{beta}2{gamma}2S (het-YFP) or {alpha}1(A322D)-YFP{alpha}1-CFP{beta}2{gamma}2S (het-CFP) and their plasma membranes were labeled with FM 4-64 (M, red). YFP fluorescence is colored green and CFP fluorescence is colored blue. Imaging of the wild type {alpha}1-FP subunit is labeled WT and imaging of the {alpha}1(A322D)-FP subunits are labeled AD. {alpha}1-CFP that colocalized (Co) with FM 4-64 is colored purple and {alpha}1-YFP that colocalized with FM 4-64 is colored yellow. B, the fraction of each {alpha}1-FP that colocalized with the plasma membrane marker was graphed.

 
Quantification of the amount of membrane and intracellular {alpha}1-FP subunit (Fig. 8B) demonstrated that with {alpha}1-CFP{alpha}1(A322D)-YFP{beta}2{gamma}2S receptors (het-CFP), 32 ± 2% of {alpha}1-CFP and 14 ± 3% of {alpha}1(A322D)-YFP subunits colocalized to the plasma membrane (n = 16, p < 0.001). Similarly, with {alpha}1-YFP{alpha}1(A322D)-CFP{beta}2{gamma}2S receptors (het-YFP), 28 ± 4% of {alpha}1-YFP and 12 ± 3% of {alpha}1(A322D)-CFP subunits were associated with the plasma membrane (n = 12, p = 0.006). The total expression of wild type {alpha}1-YFP subunit in {alpha}1-YFP{beta}2{gamma}2S receptors was ~2.2-fold higher than that of {alpha}1(A322D)-YFP subunits in homozygous mutant receptors (Fig. 4B). With heterozygous expression, the fraction of total wild type {alpha}1-FP subunit on the surface was 2.3-fold higher than the fraction of total mutant {alpha}1(A322D)-FP subunits on the cell surface (Fig. 8B). Multiplying the differences in expression (2.2-fold) with the differences in subcellular distribution (2.3-fold), we estimate that in heterozygous cells, the molar ratio of wild type {alpha}1-FP subunit to {alpha}1(A322D)-FP on the cell surface is ~5:1.

With both heterozygous {alpha}1-YFP{alpha}1(A322D)-CFP{beta}2{gamma}2S and {alpha}1-CFP{alpha}1(A322D)-YFP{beta}2{gamma}2S transfections, there was an apparently greater percentage of mutant {alpha}1(A322D)-FP subunit associated with the plasma membrane than in cells transfected with homozygous {alpha}1-YFP{beta}2{gamma}2S receptors and CFP-ER (Fig. 7). In the cells transfected with {alpha}1-YFP{alpha}1(A322D)-CFP{beta}2{gamma}2S and {alpha}1-CFP{alpha}1(A322D)-YFP{beta}2{gamma}2S receptors, CFP-ER could not be used to label the ER. Thus, because the ER abuts the plasma membrane in these cells, a distinct boundary between ER and membrane could not be identified. Therefore, we thought it was likely that in cells not transfected with CFP-ER, a portion of {alpha}1-FP subunit that was deemed to be colocalized with the membrane was actually associated with the ER, and thus the measured percentage of {alpha}1-FP and {alpha}1(A322D)-FP subunit associated with the membrane was overestimated. To test this hypothesis, we analyzed cells transfected with {alpha}1(A322D)-YFP{beta}2{gamma}2S receptors and CFP-ER, and when processing the images, we defined membrane-associated {alpha}1-YFP subunits by using only the inner leaflet of the FM 4-64 marker (as was done for cells transfected with {alpha}1-YFP{alpha}1(A322D)-CFP{beta}2{gamma}2S and {alpha}1-CFP{alpha}1(A322D)-YFP{beta}2{gamma}2S receptors) and not by using the distinct CFP-ER/FM 4-64 boundary as was done in Fig. 7. We found that without defining the CFP-ER/FM 4-64 boundary, the calculated amount of {alpha}1-YFP subunit colocalized to the membrane was 19 ± 3%, a significantly greater value than was calculated when using the CFP-ER/FM 4-64 boundary (5.1 ± 0.3%, n = 5, p = 0.002). Thus, the molar ratio of the membrane-associated {alpha}1-FP subunit to the {alpha}1(A322D)-FP subunit with heterozygous expression is likely larger than 5:1 as calculated above and may be as high as 19:1. This result also highlights the advantage of using, when possible, both membrane and ER markers in cells such as HEK293T cells, whose ER is diffusely distributed and thus abuts the membrane.

These results demonstrate that in the cells transfected with heterozygous {alpha}1 and {alpha}1(A322D) subunits, the majority of the mutant protein remained sequestered in the ER and only wild type {alpha}1 subunit formed GABAA receptors at the membrane surface, a result consistent with the nearly identical current kinetic profiles of wild type and heterozygous {alpha}1{beta}2{gamma}2S GABAA receptors (10).


   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
We previously demonstrated that the {alpha}1(A322D) mutation reduces {alpha}1 subunit expression in a subunit position-dependent manner. Here, we report that the trafficking of the mutant {alpha}1(A322D) subunit is altered between translation and oligomerization within the ER. Previously identified GABAA receptor epilepsy mutations altered the function (31, 32) or cell surface trafficking (11, 33, 34) of GABAA receptor subunits. In contrast, the GABAA receptor {alpha}1(A322D) epilepsy mutation that codes for a simple substitution of a charged for an uncharged amino acid in the M3 transmembrane helix has a novel mechanism by reducing {alpha}1 subunit expression at a post-translational and pre-oligomerization trafficking step.

{alpha}1(A322D) Alters {alpha}1 Subunit Trafficking after Translation but Before Receptor Assembly—We previously asserted that it was unlikely that the GCC to GAC mutation in the GABRA1 mutant subunit gene reduced {alpha}1 subunit expression by disrupting transcription or translation. Because GAC codes 11 of the 23 aspartates in the wild type {alpha}1 subunit, a codon bias against GAC is improbable. Here, we demonstrate that post-translational trafficking is altered with this mutation; the mutant {alpha}1(A322D) subunit has only immature N-linked glycosylation that is characteristic of ER-associated glycosylation. In addition, confocal microscopy demonstrated that essentially all of the {alpha}1(A322D)-YFP subunit was sequestered in the ER, whereas a substantial portion of wild type {alpha}1-YFP subunit was trafficked to the cell membrane. These trafficking differences between {alpha}1 and {alpha}1(A322D) subunits cannot be explained by reduced transcription or translation. However, the possibility of reduced translation in addition to altered trafficking cannot be excluded.



View larger version (5K):
[in this window]
[in a new window]
  		FIGURE 9.
The Torpedo marmorata {alpha}, {beta}, {gamma}, and {delta} subunit amino acid sequences were aligned with the human GABAA receptor {alpha}1-6, {beta}1-3, {gamma}1-3, and {delta} subunit sequences. Only the Torpedo subunits and human GABAA {alpha}1 subunit M3 segment sequences are shown here. This alignment demonstrated that the Torpedo {alpha}Ile-283, {beta}Ile-289, {gamma}Phe-297, and {delta}Ser-292 residues (shaded) were homologous to the GABAA {alpha}1(A322D) residue (shaded).

 
The trapping of unassembled GABAA receptor subunits in the ER identified that the {alpha}1(A322D) mutation occurred before subunit oligomerization. It has been shown that GABAA receptors require at least an {alpha} and a {beta} subunit to assemble into pentamers; homomeric GABAA receptor subunits are subject to ERAD (17, 24, 29). We extended these studies by using confocal microscopy to show that unassembled {alpha}1-YFP subunits are also retained in the ER (Fig. 6), and that unassembled {alpha}1(A322D)-YFP subunits lack Golgi-associated glycosylation (Fig. 4). Because the A322D mutation reduced {alpha}1 subunit expression to approximately the same extent in the absence of cotransfected {beta}2 and {gamma}2 subunits as in {alpha}1{beta}2{gamma}2 receptors (Fig. 1), it is clear that this mutation reduces {alpha}1 subunit expression prior to subunit oligomerization. Whereas it is possible that the {alpha}1(A322D) mutation may also affect other trafficking processes for the small fraction of {alpha}1(A322D) subunits that escape ERAD, oligomerize, and traffic to the cell surface, the bulk of {alpha}1(A322D) subunit expression reduction can be explained by ERAD alone.

Membrane Expression of Heterozygous Receptors Is Composed of Wild Type {alpha}1 Subunits—By making heterozygous transfections using dually labeled {alpha}1-YFP/{alpha}1(A322D)-CFP{beta}2{gamma}2S and {alpha}1-CFP/{alpha}1(A322D)-YFP{beta}2{gamma}2S receptors, we demonstrated that the plasma membrane expression of {alpha}1-FP{beta}2{gamma}2S receptors resulted almost exclusively from wild type {alpha}1-FP subunits and not from {alpha}1(A322D)-FP subunits. In one respect this result was expected given that the {alpha}1(A322D) mutation reduced {alpha}1 subunit expression after translation but before oligomerization and transport out of the ER. However, this result was also surprising given that we previously showed that heterozygous receptors with the {alpha}1(A322D) positioned between the two {beta}2 subunits (Het{beta}{alpha}{beta}) produce relatively large GABA-evoked peak currents (335 ± 87 pA) (10)), a result that implied that substantial the {alpha}1(A322D) subunit trafficked to the plasma membrane in heterozygous receptors. One explanation for this apparent discrepancy was that even though Het{beta}{alpha}{beta} produced relatively large GABA-evoked currents, they were still only 35% of wild type receptor currents. Therefore, one would expect that approximately only 25% of the {alpha}1 subunit on the cell surface contained the mutant {alpha}1(A322D) subunit, a result that could be consistent with our confocal microscopy studies (5-17%). A second explanation for this apparent contradiction is that the construction of Het{beta}{alpha}{beta} and Het{beta}{alpha}{gamma} receptors were forced using subunit concatamers. The mechanisms that target untethered {alpha}1(A322D) subunits for degradation might not apply to larger concatamer subunits. Finally, it is possible that the {gamma}{beta}{alpha}(A322D) concatamer may fold more efficiently than the {alpha}1(A322D) monomeric subunit and thus not even activate ERAD mechanisms.

{alpha}1(A322D) Subunit Misfolding May Cause ERAD—We hypothesize that the mechanism by which the A322D mutation reduced {alpha}1(A322D) expression was by misfolding and ERAD (35, 36). Could a single point mutation cause misfolding of the majority of translated {alpha}1 protein? It has been shown in model peptides that at neutral or high pH, a single aspartate positioned near the center of a transmembrane helix would disrupt the helix to allow the aspartate to reside near the aqueous surface (37). Therefore, at physiological pH, it may be expected that a substantial number of {alpha}1(A322D) M3 segments would fail to form stable transmembrane helices after translation. These misfolded subunits could then be targeted for degradation via ERAD.

The Torpedo AChR three-dimensional structure has been determined and each of its four subunit M3 segments have been demonstrated to be {alpha} helical (6). Because the primary structure of the Torpedo marmorata AChR four subunits are homologous to GABAA receptor subunits, we determined the effect on predicted helix formation of placing an aspartate position 7 of the M3 helices of the Torpedo AChR {alpha}, {beta}, {gamma}, and {delta} subunits. Alignment of the GABAA receptor subunits and Torpedo AChR subunits demonstrated that the Torpedo {alpha}Ile-283, {beta}Ile-289, {gamma}Phe-297, and {delta}Ser-292 residues (numbering from the mature protein) were homologous to the GABAA {alpha}1(A322) residue (Fig. 9). Each of the transmembrane helix prediction algorithms (DAS, TopPred, TMPred, and TMHMM) accurately identified with good confidence that the M3 segments from each Torpedo AChR subunit were transmembrane helices. Interestingly, when the sequences of each subunit were reanalyzed with {alpha}Ile-283, {beta}Ile-289, {gamma}Phe-297, or {delta}Ser-292 residues changed to an aspartate, the transmembrane helix prediction algorithms identified M3 as a transmembrane helix with substantially lower confidence than without the aspartate substitution. Not surprisingly, the confidence reduction was most significant when using the ToPred algorithm (p < 0.001), a method that is based upon the clustering of hydrophobic residues. The reduction of confidence of forming a transmembrane helix was also significant using the TMPRED (p = 0.005) and DAS (p = 0.02), but not the THMM (p = 0.1) algorithms. These theoretical analyses suggest that the substitution of an aspartate at position 7 of an M3 segment destabilizes, but does not preclude, formation of a transmembrane helix, a hypothesis that needs to be verified empirically.

We hypothesize that the misfolding and subsequent elimination of the mutant {alpha}1(A322D) subunit in ADJME is similar to the misfolding and elimination of the cystic fibrosis transmembrane regulator protein (38, 39). The majority of the cases of cystic fibrosis are caused by a deletion mutation, {Delta}Phe-508, in its cytoplasmic loop. Like the {alpha}1(A322D) mutation, the cystic fibrosis transmembrane regulator {Delta}Phe-508 retains high mannose core glycosylated and sequestered in the ER. Cystic fibrosis transmembrane regulator {Delta}Phe-508 has been shown to misfold and undergo rapid ERAD via the 26 S proteasome.

It should be emphasized that our studies were performed in fibroblasts and not in neurons. Although protein trafficking in neurons differs from that in fibroblasts, we suggest that because the trafficking error occurs before oligomerization, it is likely that in neurons the mutant {alpha}1(A322D) subunit would also undergo ERAD. However, it is also possible that overexpression of the {alpha}1(A322D) subunit (either in fibroblasts or cultured neurons) may overwhelm protein folding mechanisms and that increased ERAD of the {alpha}1(A322D) subunit protein would not occur to such an extent in a more physiologic expression system. It would be of substantial interest to create this mutation in a transgenic animal. We predict that in a heterozygous {alpha}1(A322D) knock-in mouse, the wild type {alpha}1 subunit would likely be trafficked to the cell surface and the mutant {alpha}1(A322D) subunit would undergo ERAD, producing a mouse that, like the heterozygous {alpha}1 knock-out mouse, would have fewer total brain GABAA receptors (40-42).


   FOOTNOTES
 
* This work was supported by United States Public Health Service Grants K08NS44257-01 (to M. J. G.), NS33300 (to R. L. M.), and NS39479 (to R. L. M.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

1 To whom correspondence should be addressed: Dept. of Neurology, Vanderbilt University, 6140 Medical Research Bldg. III, 465 21st Ave. South, Nashville, TN 37232-8552. Tel.: 615-322-5979; Fax: 615-322-5517; E-mail: Martin.Gallagher{at}Vanderbilt.edu.

2 The abbreviations used are: GABA, {gamma}-aminobutyric acid; AChR, nicotinic acetylcholine receptor; GABAA receptor, {gamma}-aminobutyric acid receptor type A; M3, transmembrane domain 3; ER, endoplasmic reticulum; ERAD, endoplasmic reticulum-associated degradation; FP, fluorescent protein; CFP, cyan fluorescent protein; YFP, yellow fluorescent protein; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GFP, green fluorescent protein; IDV, integrated density volume; endo-H, endoglycosidase H; PNGaseF, peptide N-glycosidase-F; WT, wild type; AFU, arbitrary fluorescence units. Back


   ACKNOWLEDGMENTS
 
We thank Dr. Aurelio Galli for critical reading of this manuscript.



   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Macdonald, R. L., and Olsen, R. W. (1994) Annu. Rev. Neurosci. 17, 569-602[Medline] [Order article via Infotrieve]
  2. McKernan, R. M., and Whiting, P. J. (1996) Trends Neurosci. 19, 139-143[CrossRef][Medline] [Order article via Infotrieve]
  3. Tretter, V., Ehya, N., Fuchs, K., and Sieghart, W. (1997) J. Neurosci. 17, 2728-2737[Abstract/Free Full Text]
  4. Baumann, S. W., Baur, R., and Sigel, E. (2001) J. Biol. Chem. 276, 36275-36280[Abstract/Free Full Text]
  5. Baumann, S. W., Baur, R., and Sigel, E. (2002) J. Biol. Chem. 277, 46020-46025[Abstract/Free Full Text]
  6. Miyazawa, A., Fujiyoshi, Y., and Unwin, N. (2003) Nature 424, 949-955
  7. Cossette, P., Liu, L., Brisebois, K., Dong, H., Lortie, A., Vanasse, M., Saint-Hilaire, J. M., Carmant, L., Verner, A., Lu, W. Y., Wang, Y. T., and Rouleau, G. A. (2002) Nat. Genet. 31, 184-189[CrossRef][Medline] [Order article via Infotrieve]
  8. Genton, P., and Gelisse, P. (2001) Arch. Neurol. 58, 1487-1490[Free Full Text]
  9. Fisher, J. L. (2004) Neuropharmacology 46, 629-637[CrossRef][Medline] [Order article via Infotrieve]
  10. Gallagher, M. J., Song, L., Arain, F., and Macdonald, R. L. (2004) J. Neurosci. 24, 5570-5578[Abstract/Free Full Text]
  11. Kang, J., and Macdonald, R. L. (2004) J. Neurosci. 24, 8672-8677[Abstract/Free Full Text]
  12. Greenfield, L. J., Jr., Sun, F., Neelands, T. R., Burgard, E. C., Donnelly, J. L., and Macdonald, R. L. (1997) Neuropharmacology 36, 63-73[CrossRef][Medline] [Order article via Infotrieve]
  13. Chiara, D. C., and Cohen, J. B. (1997) J. Biol. Chem. 272, 32940-32950[Abstract/Free Full Text]
  14. Bolte, S., Brown, S., and Satiat-Jeunemaitre, B. (2004) J. Cell Sci. 117, 943-954[Abstract/Free Full Text]
  15. Crameri, A., Whitehorn, E. A., Tate, E., and Stemmer, W. P. (1996) Nat. Biotechnol. 14, 315-319[CrossRef][Medline] [Order article via Infotrieve]
  16. Hinkle, D. J., Bianchi, M. T., and Macdonald, R. L. (2003) BioTechniques 35, 472-474, 476[Medline] [Order article via Infotrieve]
  17. Connolly, C. N., Krishek, B. J., McDonald, B. J., Smart, T. G., and Moss, S. J. (1996) J. Biol. Chem. 271, 89-96[Abstract/Free Full Text]
  18. Klausberger, T., Sarto, I., Ehya, N., Fuchs, K., Furtmuller, R., Mayer, B., Huck, S., and Sieghart, W. (2001) J. Neurosci. 21, 9124-9133[Abstract/Free Full Text]
  19. Klausberger, T., Ehya, N., Fuchs, K., Fuchs, T., Ebert, V., Sarto, I., and Sieghart, W. (2001) J. Biol. Chem. 276, 16024-16032[Abstract/Free Full Text]
  20. Klausberger, T., Fuchs, K., Mayer, B., Ehya, N., and Sieghart, W. (2000) J. Biol. Chem. 275, 8921-8928[Abstract/Free Full Text]
  21. Bollan, K., King, D., Robertson, L. A., Brown, K., Taylor, P. M., Moss, S. J., and Connolly, C. N. (2003) J. Biol. Chem. 278, 4747-4755[Abstract/Free Full Text]
  22. Taylor, P. M., Thomas, P., Gorrie, G. H., Connolly, C. N., Smart, T. G., and Moss, S. J. (1999) J. Neurosci. 19, 6360-6371[Abstract/Free Full Text]
  23. Taylor, P. M., Connolly, C. N., Kittler, J. T., Gorrie, G. H., Hosie, A., Smart, T. G., and Moss, S. J. (2000) J. Neurosci. 20, 1297-1306[Abstract/Free Full Text]
  24. Gorrie, G. H., Vallis, Y., Stephenson, A., Whitfield, J., Browning, B., Smart, T. G., and Moss, S. J. (1997) J. Neurosci. 17, 6587-6596[Abstract/Free Full Text]
  25. Buller, A. L., Hastings, G. A., Kirkness, E. F., and Fraser, C. M. (1994) Mol. Pharmacol. 46, 858-865[Abstract]
  26. Helenius, A., and Aebi, M. (2004) Annu. Rev. Biochem. 73, 1019-1049[CrossRef][Medline] [Order article via Infotrieve]
  27. Matsuda, S., Hannen, R., Matsuda, K., Yamada, N., Tubbs, T., and Yuzaki, M. (2004) Eur. J. Neurosci. 19, 1683-1690[CrossRef][Medline] [Order article via Infotrieve]
  28. Kittler, J. T., Wang, J., Connolly, C. N., Vicini, S., Smart, T. G., and Moss, S. J. (2000) Mol. Cell. Neurosci. 16, 440-452[Medline] [Order article via Infotrieve]
  29. Connor, J. X., Boileau, A. J., and Czajkowski, C. (1998) J. Biol. Chem. 273, 28906-28911[Abstract/Free Full Text]
  30. Krampfl, K., Maljevic, S., Cossette, P., Ziegler, E., Rouleau, G. A., Lerche, H., and Bufler, J. (2005) Eur. J. Neurosci. 22, 10-20[CrossRef][Medline] [Order article via Infotrieve]
  31. Bianchi, M. T., Song, L., Zhang, H., and Macdonald, R. L. (2002) J. Neurosci. 22, 5321-5327[Abstract/Free Full Text]
  32. Dibbens, L. M., Feng, H. J., Richards, M. C., Harkin, L. A., Hodgson, B. L., Scott, D., Jenkins, M., Petrou, S., Sutherland, G. R., Scheffer, I. E., Berkovic, S. F., Macdonald, R. L., and Mulley, J. C. (2004) Hum. Mol. Genet. 13, 1315-1319[Abstract/Free Full Text]
  33. Sancar, F., and Czajkowski, C. (2004) J. Biol. Chem. 279, 47034-47039[Abstract/Free Full Text]
  34. Hales, T. G., Tang, H., Bollan, K. A., Johnson, S. J., King, D. P., McDonald, N. A., Cheng, A., and Connolly, C. N. (2005) Mol. Cell. Neurosci. 29, 120-127[CrossRef][Medline] [Order article via Infotrieve]
  35. Hampton, R. Y. (2002) Curr. Opin. Cell Biol. 14, 476-482[CrossRef][Medline] [Order article via Infotrieve]
  36. Hirsch, C., Jarosch, E., Sommer, T., and Wolf, D. H. (2004) Biochim. Biophys. Acta 1695, 215-223[Medline] [Order article via Infotrieve]
  37. Caputo, G. A., and London, E. (2004) Biochemistry 43, 8794-8806[CrossRef][Medline] [Order article via Infotrieve]
  38. Gregersen, N., Bross, P., Jorgensen, M. M., Corydon, T. J., and Andresen, B. S. (2000) J. Inherit. Metab. Dis. 23, 441-447[CrossRef][Medline] [Order article via Infotrieve]
  39. Amaral, M. D. (2004) J. Mol. Neurosci. 23, 41-48[CrossRef][Medline] [Order article via Infotrieve]
  40. Kralic, J. E., Korpi, E. R., O'Buckley, T. K., Homanics, G. E., and Morrow, A. L. (2002) J. Pharmacol. Exp. Ther. 302, 1037-1045[Abstract/Free Full Text]
  41. Kralic, J. E., O'Buckley, T. K., Khisti, R. T., Hodge, C. W., Homanics, G. E., and Morrow, A. L. (2002) Neuropharmacology 43, 685-694[CrossRef][Medline] [Order article via Infotrieve]
  42. Vicini, S., Ferguson, C., Prybylowski, K., Kralic, J., Morrow, A. L., and Homanics, G. E. (2001) J. Neurosci. 21, 3009-3016[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J. Neurosci.Home page
J.-Q. Kang, W. Shen, and R. L. Macdonald
Two Molecular Pathways (NMD and ERAD) Contribute to a Genetic Epilepsy Associated with the GABAA Receptor GABRA1 PTC Mutation, 975delC, S326fs328X
J. Neurosci., March 4, 2009; 29(9): 2833 - 2844.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
J.-Q. Kang, W. Shen, and R. L. Macdonald
The GABRG2 Mutation, Q351X, Associated with Generalized Epilepsy with Febrile Seizures Plus, Has Both Loss of Function and Dominant-Negative Suppression
J. Neurosci., March 4, 2009; 29(9): 2845 - 2856.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
W.-y. Lo, E. J. Botzolakis, X. Tang, and R. L. Macdonald
A Conserved Cys-loop Receptor Aspartate Residue in the M3-M4 Cytoplasmic Loop Is Required for GABAA Receptor Assembly
J. Biol. Chem., October 31, 2008; 283(44): 29740 - 29752.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
C. A. Bradley, C. Taghibiglou, G. L. Collingridge, and Y. T. Wang
Mechanisms Involved in the Reduction of GABAA Receptor {alpha}1-Subunit Expression Caused by the Epilepsy Mutation A322D in the Trafficking-competent Receptor
J. Biol. Chem., August 8, 2008; 283(32): 22043 - 22050.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
M. Grandis, T. Vigo, M. Passalacqua, M. Jain, S. Scazzola, V. La Padula, M. Brucal, F. Benvenuto, L. Nobbio, A. Cadoni, et al.
Different cellular and molecular mechanisms for early and late-onset myelin protein zero mutations
Hum. Mol. Genet., July 1, 2008; 17(13): 1877 - 1889.
[Abstract] [Full Text] [PDF]

Home page
 Plant CellHome page
R. Muller, A. Bleckmann, and R. Simon
The Receptor Kinase CORYNE of Arabidopsis Transmits the Stem Cell-Limiting Signal CLAVATA3 Independently of CLAVATA1
PLANT CELL, April 1, 2008; 20(4): 934 - 946.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
M. J. Gallagher, L. Ding, A. Maheshwari, and R. L. Macdonald
The GABAA receptor {alpha}1 subunit epilepsy mutation A322D inhibits transmembrane helix formation and causes proteasomal degradation
PNAS, August 7, 2007; 104(32): 12999 - 13004.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
M. S. Mavinakere, C. D. Williamson, V. S. Goldmacher, and A. M. Colberg-Poley
Processing of Human Cytomegalovirus UL37 Mutant Glycoproteins in the Endoplasmic Reticulum Lumen prior to Mitochondrial Importation
J. Virol., July 15, 2006; 80(14): 6771 - 6783.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
J.-Q. Kang, W. Shen, and R. L. Macdonald
Why Does Fever Trigger Febrile Seizures? GABAA Receptor {gamma}2 Subunit Mutations Associated with Idiopathic Generalized Epilepsies Have Temperature-Dependent Trafficking Deficiencies
J. Neurosci., March 1, 2006; 26(9): 2590 - 2597.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
280/45/37995    most recent
M508305200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gallagher, M. J.
Right arrow Articles by Macdonald, R. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gallagher, M. J.
Right arrow Articles by Macdonald, R. L.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2005 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement